Account Info
Log Out
English
Back
Log in to access Online Inquiry
Back to the Top

Update

$Exicure(XCUR.US)$ EXICURE XCUR PATENT AGREEMENT WITH BLUEJAY; HELIUS HSDT FDA FEEDBACK
BPC UPDATE 02/06/2024 ET
Pre-Market Updates
Exicure Inc (NASDAQ: XCUR) announced that it has licensed some of its patents to Bluejay Thearapeutics for advanced clinical development on the treatment of hepatitis. Bluejay will receive an exclusive license in the field of hepatitis to all of Exicure’s relevant patents. Bluejay paid Exicure an initial small, one-time payment after the execution of the deal.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only. Read more
1
+0
3
Translate
Report
3212 Views
Comment
Sign in to post a comment
2036Followers
31Following
24KVisitors
Follow